JP2021512906A5 - - Google Patents
Info
- Publication number
- JP2021512906A5 JP2021512906A5 JP2020542621A JP2020542621A JP2021512906A5 JP 2021512906 A5 JP2021512906 A5 JP 2021512906A5 JP 2020542621 A JP2020542621 A JP 2020542621A JP 2020542621 A JP2020542621 A JP 2020542621A JP 2021512906 A5 JP2021512906 A5 JP 2021512906A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- patient
- use according
- migalastat
- pregnancy
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024112288A JP2024161361A (ja) | 2018-02-06 | 2024-07-12 | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862626955P | 2018-02-06 | 2018-02-06 | |
| US62/626,955 | 2018-02-06 | ||
| PCT/US2019/016841 WO2019157047A1 (en) | 2018-02-06 | 2019-02-06 | Use of migalastat for treating fabry disease in pregnant patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024112288A Division JP2024161361A (ja) | 2018-02-06 | 2024-07-12 | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512906A JP2021512906A (ja) | 2021-05-20 |
| JP2021512906A5 true JP2021512906A5 (https=) | 2022-02-15 |
| JPWO2019157047A5 JPWO2019157047A5 (https=) | 2022-02-15 |
| JP7555818B2 JP7555818B2 (ja) | 2024-09-25 |
Family
ID=65494618
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542621A Active JP7555818B2 (ja) | 2018-02-06 | 2019-02-06 | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
| JP2024112288A Pending JP2024161361A (ja) | 2018-02-06 | 2024-07-12 | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024112288A Pending JP2024161361A (ja) | 2018-02-06 | 2024-07-12 | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11357784B2 (https=) |
| EP (2) | EP4717319A2 (https=) |
| JP (2) | JP7555818B2 (https=) |
| KR (1) | KR20200128676A (https=) |
| CN (1) | CN111971044A (https=) |
| AU (2) | AU2019217868A1 (https=) |
| CA (1) | CA3090496C (https=) |
| WO (1) | WO2019157047A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2573498T3 (es) | 2006-05-16 | 2016-06-08 | Amicus Therapeutics, Inc. | Opciones de tratamiento para la enfermedad de Fabry |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| CA3224537C (en) | 2017-05-30 | 2025-09-09 | Amicus Therapeutics, Inc. | USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE |
| CA3090496C (en) | 2018-02-06 | 2024-03-26 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| EP4282472A3 (en) * | 2018-08-20 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| EP3851105B1 (en) | 2019-08-07 | 2026-03-04 | Amicus Therapeutics, Inc. | Migalastat for use in treating fabry disease in patients having a mutation in the gla gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| SG155257A1 (en) * | 2004-09-24 | 2009-09-30 | Beth Israel Hospital | Methods of diagnosing and treating complications of pregnancy |
| PL2027137T3 (pl) | 2005-06-08 | 2015-08-31 | Amicus Therapeutics Inc | Oczyszczanie imino- i aminocukrów |
| ES2573498T3 (es) | 2006-05-16 | 2016-06-08 | Amicus Therapeutics, Inc. | Opciones de tratamiento para la enfermedad de Fabry |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2150254A4 (en) | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| US8321148B2 (en) | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| JP5739898B2 (ja) | 2009-11-17 | 2015-06-24 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３） |
| CN103974619B (zh) | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| HK1209625A1 (en) | 2012-07-17 | 2016-04-08 | Amicus Therapeutics, Inc. | Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation |
| KR102004114B1 (ko) | 2016-03-22 | 2019-07-26 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| AR109103A1 (es) | 2016-07-19 | 2018-10-31 | Amicus Therapeutics Inc | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert |
| TW201829770A (zh) | 2017-01-10 | 2018-08-16 | 美商阿米庫斯醫療股份有限公司 | 用於治療fabry氏病之重組α-半乳糖苷酶A |
| CA3224537C (en) | 2017-05-30 | 2025-09-09 | Amicus Therapeutics, Inc. | USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE |
| IL272893B2 (en) | 2017-08-28 | 2024-07-01 | Amicus Therapeutics Inc | Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease |
| SMT202400027T1 (it) | 2018-02-06 | 2024-03-13 | Amicus Therapeutics Inc | Trattamento di pazienti con malattia di fabry classica con migalastat |
| CA3090496C (en) | 2018-02-06 | 2024-03-26 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| EP4282472A3 (en) | 2018-08-20 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| AR120055A1 (es) | 2019-06-11 | 2022-02-02 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal |
| EP3851105B1 (en) | 2019-08-07 | 2026-03-04 | Amicus Therapeutics, Inc. | Migalastat for use in treating fabry disease in patients having a mutation in the gla gene |
| FI4103178T3 (fi) | 2020-02-10 | 2026-03-23 | Amicus Therapeutics Inc | Menetelmiä fabryn taudin hoitamiseksi |
-
2019
- 2019-02-06 CA CA3090496A patent/CA3090496C/en active Active
- 2019-02-06 EP EP25221383.0A patent/EP4717319A2/en active Pending
- 2019-02-06 WO PCT/US2019/016841 patent/WO2019157047A1/en not_active Ceased
- 2019-02-06 KR KR1020207025691A patent/KR20200128676A/ko active Pending
- 2019-02-06 CN CN201980024425.7A patent/CN111971044A/zh active Pending
- 2019-02-06 EP EP19706178.1A patent/EP3749307B1/en active Active
- 2019-02-06 US US16/967,827 patent/US11357784B2/en active Active
- 2019-02-06 JP JP2020542621A patent/JP7555818B2/ja active Active
- 2019-02-06 AU AU2019217868A patent/AU2019217868A1/en not_active Abandoned
-
2022
- 2022-06-13 US US17/838,820 patent/US20220387462A1/en active Pending
-
2024
- 2024-07-12 JP JP2024112288A patent/JP2024161361A/ja active Pending
- 2024-12-11 AU AU2024278298A patent/AU2024278298A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512906A5 (https=) | ||
| JP2011509295A5 (https=) | ||
| JP2005537268A5 (https=) | ||
| JP2015512406A5 (https=) | ||
| WO2007143674A2 (en) | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies | |
| JPH06102622B2 (ja) | 肥満の治療 | |
| MX2014006547A (es) | Tratamiento combinado del cancer. | |
| JP2021193148A5 (https=) | ||
| JP2020200352A5 (https=) | ||
| JP7493048B2 (ja) | 経口投与用の医薬組成物 | |
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2020500864A5 (https=) | ||
| RU2009119258A (ru) | Способ лечения воспалительных заболеваний кишечника | |
| WO2024160030A1 (zh) | 一种组合物及其在制备治疗神经性疼痛药物中的应用 | |
| JP2015522077A5 (https=) | ||
| JP2004525940A (ja) | 火照りの処置のためのデュロキセチン | |
| JP2009242366A (ja) | 持続性解熱鎮痛消炎剤 | |
| US10537574B2 (en) | Use of kinase inhibitors to manage tuberculosis and other infectious diseases | |
| JP2020517670A (ja) | うつ病を治療するための組成物および方法 | |
| JPWO2019157047A5 (https=) | ||
| EP2419109B1 (en) | Method for on-demand contraception using levonorgestrel or norgestrel | |
| KR20260027165A (ko) | 의료 요법에서의 세마글루티드 | |
| JP2015520759A5 (https=) | ||
| JP7527662B2 (ja) | ピモジドとメトトレキサートの医薬組成物、及びその使用 | |
| JP2021532165A5 (https=) |